Formulations pharmacokinetics of deuterated benzoquinoline inhibitors of vesicular monoamine transporter 2

Abstract

The present invention relates to new pharmaceutical compositions comprising benzoquinoline compounds, and methods to inhibit vesicular monoamine transporter 2 (VMAT2) activity in a subject for the treatment of chronic hyperkinetic movement disorders.

What is claimed is: 
     
         1 . A solid deutetrabenazine oral dosage form comprising deutetrabenazine and a poly(ethylene oxide) polymer. 
     
     
         2 . The oral dosage form according to  claim 1  in the form of a tablet comprising a tablet core and a coating, wherein the deutetrabenazine and poly(ethylene oxide) polymer are in the tablet core. 
     
     
         3 . The oral dosage form according to  claim 1  that releases the deutetrabenazine over a period of up to about 4 hours. 
     
     
         4 . The oral dosage form according to  claim 1  that releases the deutetrabenazine over a period of up to about 8 hours. 
     
     
         5 . The oral dosage form according to  claim 1  wherein the poly(ethylene oxide) polymer is POLYOX® N60K. 
     
     
         6 . The oral dosage form according to  claim 1  comprising about 5-20% by weight of the poly(ethylene oxide) polymer. 
     
     
         7 . The oral dosage form according to  claim 1  comprising about 1-15% by weight of deutetrabenazine. 
     
     
         8 . The oral dosage form according to  claim 1  further comprising one or more of a filler, a lubricant, a binder, an absorbent, an antioxidant, a solubilizing agent, a dispersant, and a colorant. 
     
     
         9 . The oral dosage form according to  claim 1  comprising about 1-15% by weight of deutetrabenazine and about 5-20% by weight of the poly(ethylene oxide) polymer, and further comprising:
 about 60-70% by weight of a filler; 
 about 15-25% by weight of an absorbent; 
 about 1-10% by weight of a dispersant; 
 about 0.5-2% by weight of a solubilizing agent; and, 
 about 0.5-2% by weight of a lubricant. 
 
     
     
         10 . The oral dosage form according to  claim 9  further comprising about 0.1-0.2% by weight of an antioxidant. 
     
     
         11 . The oral dosage form according to  claim 10 , wherein the antioxidant is one or both of butylated hydroxyanisole and butylated hydroxytoluene. 
     
     
         12 . The oral dosage form according to  claim 11  comprising about 1-15% by weight of deutetrabenazine;
 about 5-20% by weight of a poly(ethylene oxide) polymer, 
 about 60-70% by weight of mannitol; 
 about 15-25% by weight of microcrystalline cellulose; 
 about 1-10% by weight of a polyvinylpyrrolidone; 
 about 0.5-2% by weight of a polysorbate; 
 about 0.5-2% by weight of magnesium stearate; and, 
 about 0.1-0.2% by weight of one or both of butylated hydroxyanisole and butylated hydroxytoluene.